MTOR and Parkinson disease: These data demonstrated that L-dopa administration in the PD model could lead to the overactivation of signal molecules in the D1R-mediated ERK1/2-mTOR pathway, which was consistent with the previous studies (Santini et al., 2009; Decressac and Björklund, 2013; Wu et al., 2018).